| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Model |
From the Divisions of Human Genetics* and Pathology, Cincinnati Children’s Hospital Research Foundation, Cincinnati, Ohio
Gaucher disease is an autosomal recessively inherited disease caused by mutations at the acid ß-glucosidase (GCase) locus (GBA). To develop viable models of Gaucher disease, point mutations (pmuts), encoding N370S, V394L, D409H, or D409V were introduced into the mouse GCase (gba) locus. DNA sequencing verified each unique pmut. Mutant GCase mRNAs were near wild-type (WT) levels. GCase activities were reduced to 2 to 25% of WT in liver, lung, spleen, and cultured fibroblasts from pmut/pmut or pmut/null mice. The corresponding brain GCase activities were 
25% of WT. N370S homozygosity was lethal in the neonatal period. For the other pmut mice, a few storage cells appeared in the spleen at 
7 months (D409H or D409V homozygotes) or 1 year (V394L homozygotes). V394L/null, D409H/null, or D409V/null mice showed scattered storage cells in spleen at 3 to 4 months. Occasional storage cells (sinusoidal cells) were present in liver. In D409V/null mice, large numbers of Mac-3-positive storage cells (ie, macrophages) accumulated in the lung. Glycosphingolipid analyses showed varying rates of progressive glucosylceramide accumulation in visceral organs of pmut/pmut or pmut/null mice, but not in brain. These GCase-deficient mice provide tools for gaining insight into the pathophysiology of Gaucher disease and developing improved therapies.
This article has been cited by other articles:
 |
|
 |
|
  Y. Sun, D. P. Witte, H. Ran, M. Zamzow, S. Barnes, H. Cheng, X. Han, M. T. Williams, M. R. Skelton, C. V. Vorhees, et al. Neurological deficits and glycosphingolipid accumulation in saposin B deficient mice Hum. Mol. Genet., August 1, 2008; 17(15): 2345 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P Rempel and S. G Withers Covalent inhibitors of glycosidases and their applications in biochemistry and biology Glycobiology, August 1, 2008; 18(8): 570 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. B. Enquist, C. L. Bianco, A. Ooka, E. Nilsson, J.-E. Mansson, M. Ehinger, J. Richter, R. O. Brady, D. Kirik, and S. Karlsson Murine models of acute neuronopathic Gaucher disease PNAS, October 30, 2007; 104(44): 17483 - 17488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Van Patten, H. Hughes, M. R. Huff, P. A. Piepenhagen, J. Waire, H. Qiu, C. Ganesa, D. Reczek, P. V. Ward, J. P. Kutzko, et al. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease Glycobiology, May 1, 2007; 17(5): 467 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sun, B. Quinn, Y.-H. Xu, T. Leonova, D. P. Witte, and G. A. Grabowski Conditional expression of human acid {beta}-glucosidase improves the visceral phenotype in a Gaucher disease mouse model J. Lipid Res., October 1, 2006; 47(10): 2161 - 2170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. Enquist, E. Nilsson, A. Ooka, J.-E. Mansson, K. Olsson, M. Ehinger, R. O. Brady, J. Richter, and S. Karlsson Effective cell and gene therapy in a murine model of Gaucher disease PNAS, September 12, 2006; 103(37): 13819 - 13824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Liou, A. Kazimierczuk, M. Zhang, C. R. Scott, R. S. Hegde, and G. A. Grabowski Analyses of Variant Acid beta-Glucosidases: EFFECTS OF GAUCHER DISEASE MUTATIONS J. Biol. Chem., February 17, 2006; 281(7): 4242 - 4253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sun, B. Quinn, D. P. Witte, and G. A. Grabowski Gaucher disease mouse models: point mutations at the acid {beta}-glucosidase locus combined with low-level prosaposin expression lead to disease variants J. Lipid Res., October 1, 2005; 46(10): 2102 - 2113. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
